A case of acute promyelocytic leukemia variant with derivative chromosome 3 der(3)t(3;8) associated with 8q partial gain.
Acute promyelocytic leukemia
Chromosome 8
FISH
Molecular cytogenetics
Painting
c-myc gene
Journal
Molecular cytogenetics
ISSN: 1755-8166
Titre abrégé: Mol Cytogenet
Pays: England
ID NLM: 101317942
Informations de publication
Date de publication:
2019
2019
Historique:
received:
18
03
2019
accepted:
19
06
2019
entrez:
18
7
2019
pubmed:
18
7
2019
medline:
18
7
2019
Statut:
epublish
Résumé
Acute promyelocytic leukemia (APL) is characterized by fusion of PML/RARα genes as a result of t(15;17)(q24;q21). APL is now one of the curable hematological malignancies thanks to molecularly targeted therapies based on all-trans retinoic acid (ATRA) and arsenic trioxide (ATX). Extramedullary (EM) relapse is a rare event in APL, ear involvement being even more infrequent, with only six cases so far described. About 30-35% of patients with newly diagnosed APL have additional cytogenetics abnormalities, whose prognostic significance is still controversial. The most common additional aberration is trisomy 8 or partial gain 8q. We describe here a novel unbalanced translocation der(3)t(3;8)(q29;q23.3-q24.3) associated with 8q partial gain in a 41 year-old man affected by APL in molecular remission after first line treatment, who had a responsive EM relapse in the auditory canal. EM relapse is a rare event in APL and ear involvement is even more infrequent. To our knowledge, this is the first reported case of APL with a new der(3)t(3;8)(q29;q23.3-q24.3) and 8q partial gain associated with t(15;17)(q24;q21). Despite the recurrence of the disease at EM level, the clinical outcome of this patients was favorable.
Sections du résumé
BACKGROUND
BACKGROUND
Acute promyelocytic leukemia (APL) is characterized by fusion of PML/RARα genes as a result of t(15;17)(q24;q21). APL is now one of the curable hematological malignancies thanks to molecularly targeted therapies based on all-trans retinoic acid (ATRA) and arsenic trioxide (ATX). Extramedullary (EM) relapse is a rare event in APL, ear involvement being even more infrequent, with only six cases so far described. About 30-35% of patients with newly diagnosed APL have additional cytogenetics abnormalities, whose prognostic significance is still controversial. The most common additional aberration is trisomy 8 or partial gain 8q.
CASE PRESENTATION
METHODS
We describe here a novel unbalanced translocation der(3)t(3;8)(q29;q23.3-q24.3) associated with 8q partial gain in a 41 year-old man affected by APL in molecular remission after first line treatment, who had a responsive EM relapse in the auditory canal.
CONCLUSIONS
CONCLUSIONS
EM relapse is a rare event in APL and ear involvement is even more infrequent. To our knowledge, this is the first reported case of APL with a new der(3)t(3;8)(q29;q23.3-q24.3) and 8q partial gain associated with t(15;17)(q24;q21). Despite the recurrence of the disease at EM level, the clinical outcome of this patients was favorable.
Identifiants
pubmed: 31312256
doi: 10.1186/s13039-019-0445-1
pii: 445
pmc: PMC6612227
doi:
Types de publication
Case Reports
Langues
eng
Pagination
32Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
Haematologica. 2000 Jul;85(7):758-62
pubmed: 10897129
J Clin Oncol. 2001 Oct 1;19(19):3993-5
pubmed: 11579122
J Clin Oncol. 2001 Oct 15;19(20):4023-8
pubmed: 11600603
Blood. 2002 Apr 15;99(8):2985-91
pubmed: 11929790
Leukemia. 2002 Jun;16(6):1127-30
pubmed: 12040443
Br J Haematol. 2003 Jan;120(2):266-70
pubmed: 12542484
Cancer Genet Cytogenet. 2003 Jan 1;140(1):78-81
pubmed: 12550765
Int J Hematol. 2004 Jun;79(5):462-4
pubmed: 15239396
Cancer Genet Cytogenet. 2004 Aug;153(1):81-3
pubmed: 15325101
Leukemia. 2006 Jan;20(1):35-41
pubmed: 16307026
Int J Hematol. 2009 May;89(4):489-496
pubmed: 19340529
Haematologica. 2010 Mar;95(3):424-31
pubmed: 19903674
Pediatr Blood Cancer. 2010 Apr;54(4):603-5
pubmed: 19998465
J Pediatr Hematol Oncol. 2010 Apr;32(3):229-32
pubmed: 20186102
Acta Haematol. 2010;123(3):162-70
pubmed: 20224268
Blood. 2010 Jul 22;116(3):354-65
pubmed: 20385793
J Exp Med. 2010 Nov 22;207(12):2581-94
pubmed: 21059853
Best Pract Res Clin Haematol. 2014 Mar;27(1):63-8
pubmed: 24907018
Leuk Res. 2015 Mar;39(3):265-72
pubmed: 25592059
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Am J Blood Res. 2015 Dec 25;5(2):91-4
pubmed: 27069757
Ann Oncol. 2016 Aug;27(8):1474-81
pubmed: 27084953
J Clin Diagn Res. 2017 Mar;11(3):XE05-XE08
pubmed: 28511493
Cancer Cell. 2017 Nov 13;32(5):552-560
pubmed: 29136503
Leukemia. 2018 Aug;32(8):1671-1678
pubmed: 30026570
J Assoc Genet Technol. 2018;44(3):92-99
pubmed: 30208012
Intern Med. 1997 Jul;36(7):484-6
pubmed: 9240497
Cancer. 1998 Oct 15;83(8):1522-8
pubmed: 9781945
Leuk Res. 1998 Nov;22(11):1015-9
pubmed: 9783804